文献速递淋巴瘤

修订版国际预后指数与基因改变同弥漫大B细胞淋巴瘤R-CHOP早期治疗失败相关

Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2021-10-10

R-IPI是EF最重要预测因素,NOTCH2突变及5p15·33、12q13、12q14·1、12q15获得独立于R-IPI预测EF。

要点

  • R-IPI是预测DLBCL患者R-CHOP早期治疗失败的最重要临床因素。
  • NOTCH2突变及5p15·33、12q13、12q14·1、12q15获得可独立于R-IPI预测早期治疗失败。
  • 早期治疗失败患者总生存显著缩短,应作为高危人群识别。

核心结论

  • R-IPI和特定基因改变(NOTCH2突变及5p15·33、12q13、12q14·1、12q15获得)与DLBCL患者R-CHOP早期治疗失败相关。

研究设计与样本

  • 回顾性分析373例统一接受R-CHOP治疗的DLBCL患者,其中111例进行106个基因的靶向下一代测序,87例进行拷贝数改变分析,39例进行基因表达谱分析。

主要发现

  • 伴有B症状、晚期分期、血清LDH或β2微球蛋白水平高、淋巴细胞/单核细胞比值低及R-IPI评分较高的患者更常见早期治疗失败。
  • 伴有BCL2重排的患者更常见早期治疗失败。
  • 逻辑回归显示R-IPI是早期治疗失败最重要的预测因素。
  • NOTCH2突变及5p15·33、12q13、12q14·1、12q15获得对早期治疗失败的预测重要性独立于R-IPI。

临床怎么用

  • 对DLBCL患者可结合R-IPI及NOTCH2突变、5p15·33、12q13、12q14·1、12q15获得等基因改变识别早期治疗失败高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) cases have a poor outcome. Here we analysed clinico-biological features in 373 DLBCL patients homogeneously treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP), in order to identify variables associated with early failure to treatment (EF), defined as primary refractoriness or relapse within 12 months from diagnosis. In addition to clinical features, mutational status of 106 genes was studied by targeted next-generation sequencing in 111 cases, copy number alterations in 87, and gene expression profile (GEP) in 39. Ninety-seven cases (26%) were identified as EF and showed significantly shorter overall survival (OS). Patients with B symptoms, advanced stage, high levels of serum lactate dehydrogenase (LDH) or β2-microglobulin, low lymphocyte/monocyte ratio and higher Revised International Prognostic Index (R-IPI) scores, as well as those with BCL2 rearrangements more frequently showed EF, with R-IPI being the most important in logistic regression. Mutations in NOTCH2, gains in 5p15·33 (TERT), 12q13 (CDK2), 12q14·1 (CDK4) and 12q15 (MDM2) showed predictive importance for EF independently from R-IPI. GEP studies showed that EF cases were significantly enriched in sets related to cell cycle regulation and inflammatory response, while cases in response showed over-representation of gene sets related to extra-cellular matrix and tumour microenvironment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dlouhy I, Karube K, Enjuanes A, et al. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. Br J Haematol. 2021. PMID: 34632572. doi:10.1111/bjh.17858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。